Emergent Biosolutions

- NYSE:EBS
Last Updated 2021-07-26
  • As a global specialty pharmaceutical company, Emergent offers specialized products to healthcare providers and governments to address
  • Locations

    • Rockville MD
  • Total Funding (USD)

    2.0 million
  • Acquisitions (6)

    • Adapt Pharma (2018)
    • PaxVax (2018)
    • Sanofi - smallpox vaccine (2017)
    • Cangene (2013)
    • Trubion Pharmaceuticals (2010)
    • Microscience (2005)
  • Security

    Type: ORD
    CUSIP: 29089Q105
    ISIN: US29089Q1058
Filter date
All
Bookmark Created by Last updated
There were no results found.
Filter date
All
Article Author Published
There were no results found.

Request a demo to view additional historical data, and much more.